Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis ; volume:12 ; number:1 ; day:5 ; month:7 ; year:2022 ; pages:1-16 ; date:12.2022
Scientific reports ; 12, Heft 1 (5.7.2022), 1-16, 12.2022
- Urheber
-
Tomic, Barbara
Smoljo, Tomislav
Lalic, Hrvoje
Dembitz, Vilma
Batinic, Josip
Batinic, Drago
Bedalov, Antonio
Visnjic, Dora
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-15520-z
- URN
-
urn:nbn:de:101:1-2022082421165514849541
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tomic, Barbara
- Smoljo, Tomislav
- Lalic, Hrvoje
- Dembitz, Vilma
- Batinic, Josip
- Batinic, Drago
- Bedalov, Antonio
- Visnjic, Dora
- SpringerLink (Online service)
Ähnliche Objekte (12)
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
![Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Cyclopropanierung substituierter Pyrimidine
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Cyclopropanierung substituierter Pyrimidine
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Cyclopropanierung substituierter Pyrimidine